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A B S T R A C T
The dilemma of whether to apply surgical or drug treatment to prolactinomas has been ongoing for the past 30 years.
The aim of this study is to compare the early postoperative values of prolactin (PRL) in two groups of patients with
prolactinomas: those who underwent primary surgical-treatment, and those who underwent surgery after a dopamine
agonist (DA) therapy. We present the results of surgical treatment on a series of 161 patients with prolactinomas. Surgery
was the primary treatment in 65 patients, while 96 patients had surgery following a long-term treatment with a DA. All
surgically treated prolactinomas were operated in the standard transsphenoidal, microsurgical approach. The criteria
for hyperprolactinemia remission was a PRL level under 25 ng/ml. Early normalization of PRL was achieved in 92% of
those patients who underwent primary surgical-treatment, yet it was achieved in only 42% of patients who were operated
on after receiving a long-term drug treatment with a DA. The highest prevalence of postoperative normalization of PRL
was achieved in a group of patients with microadenomas who were primarily operated on (98%). The worst results in
postoperative normalization of PRL were found in the group of patients with macroadenomas who received a long-term
drug treatment with a DA first. These results show our surgical experience in treating prolactinomas. Using surgical
treatment, the best clinical outcome was acieved with microprolactinomas and intrasellar, well-confined macroprolacti-
nomas. Nevertheless, we stress the need of an individualized approach and recommend treatment in multidisciplinary
centres for pituitary diseases.
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surgery
Introduction
Prolactinomas or lactotropic adenomas are the most
common hormone-secreting adenomas of the pituitary
gland with a prevalence of about 45% of all pituitary
adenomas. Ninety-nine percent of these are histological-
ly-benign neoplasms.
In the last half of the 20th century, the surgical treat-
ment of prolactinomas went from being an almost com-
pletely-abandoned method, to having a sudden increase
after the reaffirmation of Hardy’s transsphenoidal mi-
crosurgical approach, to then again rapidly decreasing
after the introduction of dopamine agonists (DA)1–5. Now,
after complex consideration of the results of both modes
of treatment, the number of operated patients has once
again increased.
In the early 1970s the DAs were identified as a possi-
ble effective therapy for the treatment of hyperprolacti-
nemia6. In 1973, R.M. MacLeod and J.E. Lehmeyer re-
ported an observation of the reduction of the prolactino-
ma tumor mass under the influence of ergot alkaloids7.
Shortly thereafter, the first publications on the long-
-term effects of bromocriptine in cases of galactorrhea
and hypogonadism appeared8.
In 1978, the U.S. Food and Drug Administration
(FDA) approved the use of bromocriptine in the treat-
ment of hyperprolactinemia caused by prolactinomas9.
Subsequently, a vast number of studies described the
normalization of prolactin (PRL) levels in more than
90% of cases and significant reductions of tumor size in
571
Received for publication September 11, 2012
about 85% of patients treated with bromocriptine10. The
excitement regarding the effects of dopamine agonists
was so great that in 1982 the article, Bromocriptine re-
duces pituitary tumor size and hypersecretion. Requiem
for pituitary surgery?11, was published by R.F. Spark and
his associates. Following this publication, a widely ac-
cepted consensus followed using DAs as the first-line
treatment in patients with prolactinomas. Shortly there-
after, long-acting DAs, kabergolin and quinagolide ap-
peared in clinical use and were proven to be much more
effective than bromocriptine10,12,13.
Following the breakthrough of DA as a treatment op-
tion, it was recommended that surgical treatment be
only applied in patients with a poor response to drug
therapy, intolerance to medicament treatment, prolacti-
nomas with large cystic-parts, cases of spontaneous li-
quorrhea, cases of those with rapid development of neu-
rological deficits (as in adenoma apoplexy), or in the case
of an individual patient’s refusal of long-term drug the-
rapy14,15.
In light of these new standards for treatment, the
number of surgically treated prolactinomas rapidly de-
creased. However, soon thereafter, a new perspective was
found. It was observed that under the action of bromo-
criptine there were varying degrees of calcification, amy-
loid deposits, perivascular and interstitial fibrosis in the
extracellular space, and that the prolactinomas’ cells
contracted16–18. These changes in the adenoma tissue
complicated selective, surgical removal of the tumor, re-
sulting in significantly-lower postoperative normaliza-
tion rates of PRL19. Once again, these observations led to
a review of prolactinoma treatment methods.
Subjects and Methods
At our clinic during a 25 year period from 1982 to
2007, more than 1,300 patients with pituitary adenomas
were operated upon, of which 161 were prolactinomas
(12.4%). Surgery was the primary mode of treatment in
65 (40%) patients, while 96 (60%) patients underwent
surgery after a long-term drug therapy with a DA.
All surgically-treated prolactinomas underwent a
standard transsphenoidal, transseptal microsurgical ap-
proach operation performed by a single neurosurgeon3.
As for the definition of remission for hyperprolacti-
nemia, we used the normalization of basal values of PRL
concentrations below 25 ng/mL.
Results
The age of the patients ranged from 17–70 years, with
an average age of 37.11 years, median age of 36 years,
and a SD of 11.81. Gender: women 134 (83.22%), men 27
(16.78%).
There were 98 microprolactinomas (60.8%) and 63
macroprolactinomas (39.2%). We found a statistically-
-significant difference of the incidence of micro and macro-
adenomas between men and women (Table 1). Amongst
male patients, the majority were macroprolactinomas
(88%) while women had microprolactinomas in 70% of
cases (Table 1).
Before surgery, the serum PRL levels ranged from
40–920 ng/mL, median 160 ng/mL, mean/average value
of 207.63±158.31. After surgery, the values of PRL drop-
ped significantly from 4–250 ng/mL, median 23 ng/mL,
mean/ average value 28.26±24.55.
Following surgery, the normalization of PRL values
(<25 ng/mL) was achieved in 100 patients (62.2%) pa-
tients, while the 61 (38.8%) remaining patients had PRL
values greater than 25 ng/mL (Table 2).
In the group of primary operated-upon patients, we
found a statistically-significant difference in early post-
operative normalization of PRL between the groups of
patients with micro and macroadenomas (Table 3).
In the group of patients who were previously treated
with a DA, the postoperative difference in the normaliza-
tion of PRL between the micro and macroadenoma was
also found to be statistically significant (Table 4).
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TABLE 1
DISTRIBUTION BY GENDER AND SIZE OF ADENOMAS
Men
No (%)
Women
No (%)
Total
No (%)
Microadenomas 3 (11.11%) 95 (70.89%) 98 (60.8%)
Macroadenomas 24 (88.88%) 39 (29.10%) 63 (39.2%)
Total 27 (16.78%) 134 (83.22%) 161 (100%)
(Fisher exact test) p<0.001
TABLE 2
SUCCESS OF SURGICAL THERAPY DEPENDING ON PRIMARY
TREATMENT METHOD
Postoperative
PRL <25
ng/mL
Postoperative
PRL >25
ng/mL
Total
Primary surgical
treatment 60 (92%) 5 (8%) 65 (40.3%)
Primary treat-
ment with a DA 40 (42%) 56 (58%) 96 (59.6%)
Total 100 (62.2%) 61 (38.8%) 161 (100%)
Evidence of a statistically significant difference of postoperative
normalization of PRL frequency: PRL: c2 = 42.24, df = 1, p<
0.001.
TABLE 3
NORMALIZATION OF PRL IN PATIENTS TREATED WITH
PRIMARY SURGERY
No, (%) PRL <25ng/mL
PRL >25
ng/mL
Microprolactinomas 54 (83%) 53 (98%) 1 (2%)
Macroprolactinomas 11 (17%) 7 (63.6%) 4 (36.4%)
Fisher exact test p=0.002
PRL levels in patients with microadenomas prior to
surgery ranged from 40–270 ng/mL, median 139 ng/ml,
mean 170.07±120.16. Following surgery, PRL values fell
to 4–64 ng/mL, median 19.5 ng/mL, mean 20.37±11:43.
In the macroadenoma group, the PRL serum level before
surgery was in the range of 58–920 ng/mL, median 200
ng/ml, mean 266.05±190.77. After surgery, serum PRL
levels ranged from 8–250 ng/mL, median 35.40 ng/mL,
mean 54±30.15. The difference in values of PRL before
and after surgery was statistically significant in both
groups p<0.001 (Table 5).
The degree of invasiveness was determined on the ba-
sis of neuroradiological criteria (34, 35, 36) and the World
Health Organization’s guidelines of a five-level classifica-
tion of pituitary adenomas (37). In the group of invasive
tumors, 90% were macroadenomas where in the group of
noninvasive tumors, only 30% were macroadenomas (Ta-
ble 3). In our series, a statistically-significant difference
was found in the degree of invasiveness between micro
and macroadenomas (Fisher exact test (p<0.001)). In
our group of patients, there was a total of 22 invasive
prolactinomas, of which two were microadenomas and 20
were macroadenomas. There were 139 noninvasive ade-
nomas, of which 96 were microadenomas and 43 were
macroadenomas (Table 6).
Complications
Twenty-two patients (13.6%) had transitory diabetes
insipidus (DI) lasting up to one week. Four patients
(2.5%) had DI lasting one month and one patient (0.6%)
had DI that remained permanently. Hypocorticism was
recorded postoperatively in two patients (1.25%), and
panhypopituitarism in one patient (0.6%). One patient
(0.6%) had paresis of the abducens nerve 3 months p
ostoperatively. There was no mortality in this series.
The long-term follow-up data of operated patients has
not been completed. After the dissolution of the former
state of Yugoslavia, many patients became inaccessible,
some did not respond to the invitation for a medical ex-
amination, or the medical reports of some of the patients
were useless for proper analysis. However, reliable long-
-term monitoring of PRL values was obtained from 81
patients with a follow-up range of 2–23 years. It should
be noted that out of 52 patients who postoperatively had
acceptable values of PRL, 7 (13.46%) of them had a re-
currence of hyperprolactinemia during the long-term fol-
low-up. In two of these patients hyperprolactinemia de-
veloped after a year, in one patient after three years, in
another two patients after four years, in one after 7
years, and in one after 12 years. Three patients from this
group had recidivism of the adenoma verified by postop-
erative MRI scans, but there was no need for revisional
surgery. Two patients were treated with a DA and one
underwent treatment with Gamma Knife®.
Discussion
Our experience in primary surgical treatment of pro-
lactinomas showed improvement with a two times better
result than surgery after a DA. This is particularly evi-
dent in cases of microadenomas and intrasellar well-con-
tained /defined adenomas.
Similar experience was published by M. Losa, who
stated that in most cases, the transsphenoidal surgery of
prolactinomas can be definitive therapy, particularly in
patients with intrasellar tumors20. On the basis of simi-
lar results, A. Liuzzi responded to R.F. Spark’s publica-
tion from 1982, Bromocriptine reduces pituitary tumor
size and hypersecretion. Requiem for pituitary surge-
ry?11, by making an opposing statement and asking:
»Microprolactinomas: why requiem for surgery?«21. In a
publication by H.E. Turner in 1999, he emphasized that
patients with hyperprolactinemia, particularly those with
microprolactinomas, could often achieve satisfactory per-
manent improvement using the transsphenoidal micro-
surgical approach by an experienced neurosurgeon. He
pointed out that the cost of the operation, which often
provides a permanent cure is the same to a ten-year cost
of uncomplicated therapy with a DA22, and is also chea-
per than a lifelong drug therapy23.
In a study named »Therapeutic controversy: manage-
ment of prolactinomas«, after discussing the biological
and social circumstances of each individual patient, M.E.
Molitch and associates came to a very similar conclusion
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TABLE 5
PRL LEVELS BEFORE AND AFTER SURGERY IN GROUPS WITH
MICRO AND MACROADENOMAS
PRL before surgery
in ng/mL
PRL after surgery
in ng/mL
Microadenomas 170.07±120.16 20.37±11.43
Macroadenomas 266.05±190.77 40.54±30.15
Total 207.63±158.31 28.26±24.55
Fischer exact test, p<0.001
TABLE 6
INVASIVENESS OF PROLACTINOMA
Invasive
adenomas
Noninvasive
adenomas
Total
No (%)
Microadenomas 2 (9.09%) 96 (69.06%) 98 (60.8%)
Macroadenomas 20 (90.91%) 43 (30.94%) 63 (39.2%)
Total 22 (13.66%) 139 (86.33%) 161 (100%)
Fisher exact test p<0.001
TABLE 4
NORMALIZATION OF PRL IN PATIENTS OPERATED AFTER A
LONG-TERM DRUG THERAPY
No (%) PRL <25ng/mL
PRL >25
ng/mL
Microprolactinomas 44 (46%) 31 (70.4%) 13 (29.6%)
Macroprolactinomas 52 (54%) 9 (17.3%) 43 (82.7%)
c2=27.69; df=1; p<0.001
about the benefits of surgical therapy24. In a publication
by S.G. Soule, a low therapy success rate was presented
for prolactinomas pretreated with a DA compared with
those prolactinomas treated with surgery as the first-line
method. It was also suggested that resistance to drug
therapy is associated with resistance to surgical treat-
ment25.
Poor success rates in the normalization of PRL values
after surgery in patients pretreated with DAs could be at-
tributed to fibrous induration of the adenomas. In an ar-
ticle from 1982, A.M. Landolt reported better normaliza-
tion of PRL values in patients with microprolactinomas
who were not preoperatively treated with bromocrip-
tine26. He claimed that bromocriptine pre-treatment,
subsequent fibrosis, and loss of clear boundaries between
the adenoma and normal pituitary tissue reduces the
possibility of selective removal of the tumor, resulting in
significantly lower postoperative normalization of PRL26.
In 1986, using light microscopy, M.M. Esiri and associ-
ates also confirmed and described fibrous induration of
adenomas induced by DAs. They described an increase in
tissue fibrosis in accordance with the duration of ther-
apy. Prolonged use of DAs changes the gland and the bor-
der between normal tissue and the adenoma resulting in
an obscure difference in color and consistency making
microdissection after primary DA therapy very diffi-
cult27.
However, some authors have different and even con-
tradictory experiences concerning DA therapy28,29. M.E.
Sughrue claims that preoperative treatment with DAs, in
addition to decreasing tumor size, increases the possibil-
ity of surgical removal of the tumor and achieves better
postoperative control of prolactin30. The only study in
which there were no documented side effects of pro-
longed pretreatment with DAs, was by G. Faglia and as-
sociates dating from 1983. They discontinued medica-
ment DA therapy about 8.4 months before surgery, which
may have allowed the reversibility of bromocriptine-in-
duced changes in tumor consistency31.
Differences in treatment success between
macroprolactinomas and microprolactinomas
Our data shows that the highest incidence of normal-
ization of PRL values was achieved in a group of patients
with microadenomas primary operated upon (98%) (Ta-
ble 5). Patients with macroadenomas who were on previ-
ous long-term DA medicament therapy (17.3%) had the
worst results (Table 6).
This corresponds to the results of J.G.M. Klijn and as-
sociates who found that tumor volume is closely corre-
lated with serum PRL levels and thus becomes quite a re-
liable indicator of the expected surgical results, which
was later confirmed in several other studies32. Other au-
thors have had similar conclusions on the impact of tu-
mor size and preoperative PRL levels on the success of
the operation33. K. Sinkunas found a very high percent-
age (90%) of postoperative normalization of PRL levels in
women with microprolactinomas who were not treated
with DAs prior to surgery. He proposed that the main
prerequisites for a good final result with surgical treat-
ment of prolactinomas were younger age, noninvasive
tumors, serum prolactin values lower than 2309 mU/L,
and no usage of DAs prior to surgery34.
Invasiveness
We have found that there is a much higher incidence
of invasive adenomas in macroadenomas (Table 6), which
corresponds to the opinion that size and invasiveness are
the main factors that influence the degree of success of
the operation. R.V. Randall published that the normaliza-
tion of PRL levels occurred in 5 of 10 patients (50%) with
macroadenomas, but in only 5 of 25 (25%) patients with
invasive adenomas35. In l987, J.S. Bevan and associates
described successful treatment of only 28.6% of macro-
prolactinomas and there was not a single successful nor-
malization of PRL values in the subgroup of 8 tumors
which were invasive before surgery36. Similarly, in 1992,
J. Webster and associates reported successful treatment
in 80% of 30 patients with adenomas of 10–19 mm in di-
ameter while the treatment success in those with tumors
of 20 mm or more was only 57%37.
Arguments in favor of surgical treatment
When choosing any treatment method, possible ad-
verse effects should be kept in mind. Numerous publica-
tions warn of fibrotic changes in pituitary tissue, and in
vital organs such as the heart and lungs38–45. Additio-
nally, the European Medicines Agency (EMA) issued a
press-release in 2008 warning of increased risk of fibrosis
due to the use of bromocriptine, cabergoline, dihydro-er-
gocriptine, lisurid and pergolin.
Nausea, vomiting, dizziness, hypotension, and head-
aches were found to be frequent side-effects. Chronic use
of Das was found to cause painful peripheral vasospasms
and psychiatric symptoms (depression and anxiety), es-
pecially in those with a previous psychiatric history hav-
ing further advancement of their disease45. There is also
a possibility of liquorrhea which sometimes occurs after
contraction of macroadenomas46,47. Numerous patients
on DA therapy, despite normalization of PRL levels and
regression of clinical manifestations, often experienced
anxiety due to the fact that DAs did not destroy the tu-
mor mass itself, and is instead still present in their bod-
ies. They also feared the possibility of disease relapse af-
ter cessation of DA therapy45.
Perioperative complications of selective transsphenoi-
dal adenomectomy are rare and highly dependent on
both the expertise of the neurosurgeon and the equip-
ment of the health facility3,5,48–50. About 50% of patients
with macroadenomas were found to have various forms
of preoperative hypopituitarism related to the long-term
compressive effect of the tumor. Hypopituitarism result-
ing from operative trauma is also often seen in these pa-
tients, while improvement of the pituitary function rarely
occurs after the surgery51. Those patients with macro-
prolactinomas and hypopituitarism should receive stan-
dard adjuvant hormone therapy.
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The recurrence of hyperprolactinemia after a long pe-
riod (1–7 years) of normalization of PRL values that we
found in our series is difficult to explain. A similar obser-
vation has been described only by J.A. Thomson so far,
but with no rational explanation52. It could be the case of
a new prolactinoma growth in the remaining healthy tis-
sue of the pituitary gland or incomplete removal of the
primary tumor.
Due to the possibility of pseudoprolactinoma, it is im-
portant to emphasize that a reliable diagnosis of prolacti-
noma can be confirmed exclusively by immunohistoche-
mical verification, which is not possible without surge-
ry3,53.
The goals of prolactinoma therapy are very demand-
ing. They consist of removing symptoms and signs of
hyperprolactinemia including infertility, sexual dysfunc-
tion, osteoporosis, normalizing the hormonal status, pre-
serving residual pituitary function, correcting visual
field deficits and dysfunction of other cranial nerves, re-
moving clinical and radiological signs of tumor existence,
preventing progression or recurrence of the disease, im-
proving quality and length of the patients’ life, and pre-
venting complications. These objectives are difficult to
achieve even with the combination of multiple treatment
modalities3.
The goals of treatment for micro and macroprolacti-
nomas are similar, but for most microprolactinomas con-
trol of the tumor mass is not as clinically significant, be-
cause it will not cause neurological deficits, nor grow
quickly enough to create a potential risk over time. In
most cases of macroprolactinomas which have the poten-
tial to create neurological effects, the control of tumor
growth and its reduction in size is a priority in relation to
the treatment of hypogonadism54.
In 2006, M. Gillam and associates analyzed the re-
sults of 50 published studies of prolactinoma treatment.
With regard to the importance of tumor size and PRL
levels prior to and immediately post-surgery, they em-
phasized the expertise of neurosurgeons as the dominant
factor in achieving good postoperative results54. Accord-
ing to the results of this analysis, the rate of recidivism of
hyperprolactinemia after initial postoperative normal-
ization of PRL values varies among different clinical cen-
ters and ranges between 0 and 50 percent. It should be
noted that the majority of recidivisms were not con-
firmed by neuroradiological imaging. Patients with gi-
gantic adenomas (>40 mm) and considerable invasion of
the cavernous sinuses were found to have almost no
chance of successful surgical treatment.
Conclusion
Based on our results, our experience, and the work of
other authors, we believe that pituitary tumors should be
treated in multidisciplinary centers with an experienced
neurosurgeon. We emphasize that while the experience
and expertise of the neurosurgeon is an important factor
in treatment success, approach to the patient must be in-
dividualized. Our surgical experience (presented in this
paper) shows that primary surgical treatment of pro-
lactinomas is a viable therapeutic modality, especially in
cases of microprolactinomas and intrasellar, well con-
fined macroprolactinomas.
The limitation of this study is that it does not present
the whole cohort of patients treated. The results of exclu-
sively medicament treatment of prolactinomas are miss-
ing thus making it impossible to compare and draw con-
clusions regarding the treatment method of choice.
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PROLAKTINOMI – KIRUR[KO ILI MEDIKAMENTOZNO LIJE^ENJE?
S A @ E T A K
Dilema, operirati ili medikamentozno lije~iti prolaktinome prisutna je ve} 30 godina. Cilj ovog istra`ivanja je uspo-
rediti normalizaciju ranih postoperativnih vrijednosti prolaktina (PRL) u dvije skupine bolesnika sa prolaktinomima:
primarno kirur{ki lije~enih i onih koji su kirur{ki lije~eni nakon prethodne terapije agonistima dopamina (DA). U ovom
~lanku prezentirani su rezultati operacijskog lije~enja 161 bolesnika s prolaktinomom. Operacija je bila primarni na~in
lije~enja u 65 bolesnika, dok je 96 bolesnika operirano nakon dugotrajne medikamentozne terapije s DA. Svi kirur{ki
tretirani prolaktinomi operirani su standardnim, transsfenoidalnim, mikrokirur{kim pristupom od strane jednog ope-
ratera. Kao definiciju remisije hiperprolaktinemije koristili smo normalizaciju koncentracije bazalnih vrijednosti pro-
laktina (PRL) ispod 25 ng/mL. U primarno operiranih bolesnika postignuta je rana postoperativna normalizacija PRL u
92% slu~ajeva, a u operiranih nakon dugotrajne medikamentozne terapije sa DA u samo 42% slu~ajeva. Najbolje rezul-
tate u normalizaciji koncentracije prolaktina postigli smo u skupini bolesnika sa mikroadenomima koji su primarno
operirani (98%), a najlo{ije rezultate u skupini bolesnika s makroadenomima koji su prethodno bili na dugotrajnoj
medikamentoznoj terapiji s DA (17,3%). Ovi rezultati prikazuju na{e iskustvo u kiru{kom lije~enju prolaktinoma. Naj-
bolji klini~ki rezultat imali smo sa mikroprolaktinomima i intraselarnim, dobro ograni~enim makroprolaktinomima.
Isti~emo potrebu multidisciplinarnog i individualnog pristupa u izboru metode lije~enja.
@. Gnjidi} et al.: Surgical Treatment of Prolactinomas, Coll. Antropol. 38 (2014) 2: 571–576
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